FDA narrows compounded GLP‑1 market

The Food and Drug Administration is closing the loopholes that helped mass-marketed compounded GLP-1 weight-loss drugs spread during shortages. (fda.gov) GLP-1 drugs are medicines that mimic a gut hormone to reduce appetite and slow digestion. Approved versions include Novo Nordisk’s Wegovy and Ozempic and Eli Lilly’s Zepbound and Mounjaro. (fda.gov) Compounding is supposed to cover shortages or patient-specific needs, not create mass-market substitutes. The FDA said on February 6 that companies including Hims & Hers and some compounding pharmacies had been marketing non-approved versions as similar alternatives to approved drugs. (fda.gov) The agency also said sellers cannot call compounded products generic versions, claim they are the same as approved drugs, or say they use the same active ingredient in a way that implies equivalence. The FDA said violations could bring seizures or injunctions. (fda.gov) That crackdown followed a March 3 enforcement sweep in which the FDA sent 30 warning letters to telehealth companies over false and misleading claims about compounded GLP-1 products. The agency said it had sent thousands of ad-warning letters in the prior six months. (fda.gov) The legal backdrop changed when the FDA declared the tirzepatide injection shortage resolved on December 19, 2024, and the semaglutide injection shortage resolved on February 21, 2025. Once shortages end, compounders face tighter limits on making products that are essentially copies of commercial drugs. (fda.gov 1) (fda.gov 2) On April 1, the FDA sharpened that standard again. It said a semaglutide injection mixed with another ingredient such as vitamin B12 can still be treated as an “essentially a copy” product if the route is the same and the strengths are within 10% of approved drugs. (fda.gov) The agency left a narrow lane open for true custom compounding. Under section 503A, a prescription must be written for an individual patient, and a prescriber can justify a change only if it makes a significant difference for that patient. (fda.gov) Hims & Hers had already begun retreating from broad compounded GLP-1 marketing. On March 9, the company said it would no longer advertise compounded GLP-1 offerings on its platform or in its marketing and would shift U.S. customers toward FDA-approved medicines through a collaboration with Novo Nordisk. (investors.hims.com) That same announcement said compounded semaglutide would remain available only on a limited scale for a smaller set of patients whose needs could not be met with commercially available options. Hims & Hers said existing patients could transition to approved drugs when clinicians found that appropriate. (investors.hims.com) As regulators narrow the compounded market, large platforms are building around approved supply instead. Amazon said this month that One Medical offers weight-management care tied to Amazon Pharmacy, and Amazon Pharmacy on April 9 began offering Lilly’s oral GLP-1 Foundayo with same-day delivery in nearly 3,000 cities and towns. (aboutamazon.com) (press.aboutamazon.com) The market that grew around shortages is being pushed back toward approved brands, named manufacturers, and standard pharmacy channels. The FDA’s message is that compounding can still exist, but not as a national advertising-driven substitute business. (fda.gov)